Dirk Reyn has been appointed as chairman of the Board of Directors of flanders.bio

 

Dirk Reyn has been elected chairman of flanders.bio by the Board of Directors on 22 November 2018. With this appointment, Dirk takes up the torch from Erwin Blomsma.

With the appointment of Dirk Reyn, flanders.bio enters a new phase of its development. The ecosystem of life sciences and biotech companies has evolved considerably over the last few years. Under the leadership of Erwin Blomsma, the strategy of flanders.bio was adjusted to the needs of this changing landscape. Furthermore, as a representative of the of the knowledge intensive life sciences sector, flanders.bio has grown into a full-fledged partner of the Flemish government that selected the development and growth of the life sciences sector as one of its spearhead domains.


“My ambition is to continue on the path chosen and to fully capitalise on the results of our SME’s to help our ecosystem grow to a world-class cluster. We cannot stress enough enough that all elements to do so, are present: We have a unique mix of excellent scientific competences with a dynamic network of universities and knowledge institutions, we have a growing pool of talent and experienced entrepreneurs and we have a government that has been pursuing a consistent support policy for years. And all of this on a small and centrally located area stimulating close cooperation.” Says Dirk Reyn, Chairman of the board of flanders.bio


“The flanders.bio team and the entire board want to express its gratitude to Erwin for his commitment over the last four years and are very pleased that he is willing to continue to share his experience as vice-chairman of the Board.” continues Dirk Reyn

Note

About Dirk Reyn
Dirk Reyn is a Pharmacist/MBA with more than 30 years’ experience in the life science industry. He is currently Managing Partner of BioQube Ventures (2015). Dirk has gained commercial experience at Eli Lilly and Janssen-Cilag (Johnson & Johnson). In 2006, Dirk co-founded Movetis NV, a JNJ spin-off for GI assets. As CEO, he was instrumental in building this company, getting Resolor (a prokinetic) approved in 2009 for chronic constipation and launched in four countries with reimbursement. The same year, the company went public on Euronext and in 2010 was acquired by Shire. Since then he has co-founded Progress Pharma (2013), Lipid Therapeutics (2015) and eTheRNA, a spin-off from the University of Brussels with a breakthrough mRNA-based immunotherapy for cancer & infectious diseases (2016), Across Health (2017, Chairman of the board) and Spectricity, (2018, an Imec spin-off). Since 2013 Dirk is part of the Board of Directors of flanders.bio.


About flanders.bio
flanders.bio is a dynamic, member driven organisation with currently more than 350 members from Belgium and abroad. We help our members to create value by organising Networking and Training Activities, supporting Internationalisation, providing Services and building Expertise.
flanders.bio and its members want to be the proud advocates of a reputable global-impact ecosystem in life sciences.


flanders.bio is supported by a number of strategic partners: CMAST, Gimv, Janssen Pharmaceutica, KBC Securities, PwC, VIB and its structural partners: Flanders Investment & Trade en Agentschap Innovatie en Ondernemen.


For more info, please visit www.flanders.bio

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?